CUPID 2 is a phase 2b , double-blind , placebo-controlled , multinational , multicenter , randomized event-driven study in up to 250 patients with moderate-to-severe heart failure with reduced ejection fraction and New York Heart Association functional class II to IV symptoms despite optimal therapy .